. Author manuscript; available in PMC: 2016 Aug 25.

Published in final edited form as: Eur J Pharm Sci. 2016 May 14;91:236–242. doi: 10.1016/j.ejps.2016.05.011

Table 5. Expected absorbed doses of ¹¹¹In-CP04 in humans based on two scaling models for translating mouse to human data.

	Absorbed dose per injected activity (mGy/MBq)
Organs	Option 1	Option 2
LLI wall	0.078	0.075
Small intestine	0.026	0.024
Stomach wall	0.012	0.011
ULI wall	0.037	0.035
Heart wall	0.005	0.003
Kidneys	0.039	0.124
Liver	0.005	0.009
Lungs	0.004	0.003
Muscle	0.010	0.009
Pancreas	0.008	0.017
Red marrow	0.010	0.012
Osteogenic cells	0.015	0.034
Spleen	0.007	0.011
Urinary bladder wall	0.459	0.456
Total body	0.011	0.010
Effective dose (mSv/MBq)	0.045	0.044

Table 5. Expected absorbed doses of 111In-CP04 in humans based on two scaling models for translating mouse to human data.